KR20220000185A - A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract - Google Patents
A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract Download PDFInfo
- Publication number
- KR20220000185A KR20220000185A KR1020200077835A KR20200077835A KR20220000185A KR 20220000185 A KR20220000185 A KR 20220000185A KR 1020200077835 A KR1020200077835 A KR 1020200077835A KR 20200077835 A KR20200077835 A KR 20200077835A KR 20220000185 A KR20220000185 A KR 20220000185A
- Authority
- KR
- South Korea
- Prior art keywords
- peony
- licorice
- mixed extract
- arthritis
- extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 74
- 206010003246 arthritis Diseases 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims description 66
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 title claims description 63
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 title claims description 63
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 title claims description 63
- 229940010454 licorice Drugs 0.000 title claims description 63
- 238000011282 treatment Methods 0.000 title description 6
- 230000002265 prevention Effects 0.000 title description 4
- 240000004670 Glycyrrhiza echinata Species 0.000 title 1
- 244000170916 Paeonia officinalis Species 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 241000736199 Paeonia Species 0.000 claims description 65
- 241000202807 Glycyrrhiza Species 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 40
- 239000003674 animal food additive Substances 0.000 claims description 13
- 230000032683 aging Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229940069445 licorice extract Drugs 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 abstract description 24
- 241000282472 Canis lupus familiaris Species 0.000 abstract description 9
- 241000282326 Felis catus Species 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 6
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract description 6
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 206010007710 Cartilage injury Diseases 0.000 abstract description 5
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 5
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 4
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 description 15
- 210000000845 cartilage Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- -1 alginic acid salts Chemical class 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000005067 joint tissue Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001474977 Palla Species 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 229940092258 rosemary extract Drugs 0.000 description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염의 예방 또는 치료용 약학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing or treating arthritis comprising a peony and licorice mixed extract.
개 고양이 관절염은 이들 동물의 고령화와 동반되어 매우 흔하게 발생하는 질환이다. 현재까지 개 고양이의 관절염 질환의 예방 및 치료를 위한 효과적인 약제나 치료법은 개발되지 못하고 있다. 관절염은 노화, 물리적 손상, 면역이상 등 다양한 원인에 의해 관절 내에 염증성 변화가 생긴 것 을 지칭한다. 특히 관절염 중에서, 골관절염(osteoarthritis)은 퇴행성 관절염으로 칭해지기도 하는 관절염의 일종으로서, 연골과 주위골에 퇴행성 변화가 나타나서 생기는 관절염을 말한다. 즉, 골관절염은 관절 연골의 점차적인 소실과 더불어 연골 하방에 위치한 뼈의 비대, 관절 가장자리 부위의 골 생성, 및 비특이적인 활막 염증을 특징으로 하는 질환이다. 골관절염은 노화나 외상 등에 의해서 연골이 손상되어 발생하는 질환이다. 개 고양이에서 발생하는 골관절염은 사지 모두에서 발생할 수 있으며, 심한 통증과 운동 장애를 나타내며, 장기간 방치할 경우에는 관절의 변형까지 초래하게 된다.Arthritis in dogs and cats is a very common disease that accompanies the aging of these animals. Until now, effective drugs or treatments for the prevention and treatment of arthritis diseases in dogs and cats have not been developed. Arthritis refers to inflammatory changes in the joints due to various causes such as aging, physical damage, and immune abnormalities. In particular, among arthritis, osteoarthritis is a type of arthritis also called degenerative arthritis, and refers to arthritis caused by degenerative changes in cartilage and surrounding bones. That is, osteoarthritis is a disease characterized by gradual loss of articular cartilage, hypertrophy of the bone located below the cartilage, bone formation at the joint edge, and non-specific inflammation of the synovial membrane. Osteoarthritis is a disease caused by damage to cartilage due to aging or trauma. Osteoarthritis occurring in dogs and cats can occur in both extremities, and it presents severe pain and movement disorders, and if left unattended for a long period of time, it can even lead to joint deformation.
한편, 작약은 쌍덕잎식물로서, 꽃이 아름다워 원예용으로 많이 이용되며, 한국, 몽골, 동시베리아 등지에 분포하며, 산지에서 자란다. 뿌리는 진통·복통·월경통·무월경·토혈·빈혈·타박상 등의 약재로 쓰인다. 감초는 예로부터 약리작용이 뛰어나, 여러 한약에 들어갔으며, 특히 간염, 두드러기 피부염 습진 등에 효과가 있었다.On the other hand, the peony is a double-leaved plant, and it is widely used for horticultural purposes because of its beautiful flowers. It is distributed in Korea, Mongolia, and Siberia, and grows in mountainous areas. The root is used as medicine for pain relief, abdominal pain, menstrual pain, amenorrhea, hematemesis, anemia, and bruises. Since ancient times, licorice has excellent pharmacological effects, and has been used in various herbal medicines, especially hepatitis, urticaria, dermatitis, and eczema.
본 발명자들은 개 고양이의 관절염 치료를 위한 연구를 한 결과, 작약 및 감초 혼합 추출물이 관절염 치료에 효과가 있다는 것을 확인하고 본 발명을 완성하였다.As a result of research for the treatment of arthritis in dogs and cats, the present inventors confirmed that the mixed extract of peony and licorice was effective in treating arthritis and completed the present invention.
본 발명은 상기의 문제를 해결하기 위해 안출한 결과, 작약 및 감초 혼합 추출물이 개 고양이의 관절염에 치료효과가 있다는 것을 확인하고 본 발명을 완성하였다. As a result of devising the present invention to solve the above problems, it was confirmed that the mixed extract of peony and licorice has a therapeutic effect on arthritis in dogs and cats, and the present invention was completed.
본 발명의 목적은 작약 및 감초 혼합추출을 포함하는 관절염의 예방 또는 치료용 약학적 조성물을 제공하는 것이다. It is an object of the present invention to provide a pharmaceutical composition for preventing or treating arthritis comprising a mixed extract of peony and licorice.
본 발명의 다른 목적은 작약 및 감초 혼합 추출물을 포함하는 건강기능식품 조성물을 제공하는 것이다. Another object of the present invention is to provide a health functional food composition comprising a peony and licorice mixed extract.
본 발명의 또 다른 목적은 작약 및 감초 혼합추출을 포함하는 동물의 관절염의 예방 또는 치료용 수의학적 조성물을 제공하는 것이다. Another object of the present invention is to provide a veterinary composition for preventing or treating arthritis in animals comprising a mixed extract of peony and licorice.
본 발명의 또 다른 목적은 작약 및 감초 혼합 추출물을 포함하는 관절염 예방 또는 개선용 사료 첨가제를 제공하는 것이다. Another object of the present invention is to provide a feed additive for preventing or improving arthritis comprising a peony and licorice mixed extract.
본 발명은 작약 및 감초 혼합추출을 포함하는 관절염의 예방 또는 치료용 약학적 조성물을 제공할 수 있다. The present invention may provide a pharmaceutical composition for preventing or treating arthritis, comprising a mixed extract of peony and licorice.
상기 작약 및 감초 혼합 추출물은 열수 추출물일 수 있다. The peony and licorice mixed extract may be a hot water extract.
상기 작약 및 감초는 10:1 내지 1:1의 중량비율로 혼합되는 것일 수 있다. The peony and licorice may be mixed in a weight ratio of 10:1 to 1:1.
상기 관절염은 노화, 외상, 자가면역, 대사질환로 이루어진 군으로부터 선택되는 어느 하나로 인할 수 있다. The arthritis may be due to any one selected from the group consisting of aging, trauma, autoimmune, and metabolic diseases.
상기 작약 및 감초 혼합 추출물의 농도는 1 내지 1000mg/kg일 수 있다. The concentration of the peony and licorice mixed extract may be 1 to 1000 mg/kg.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염의 예방 또는 개선용 건강기능식품 조성물을 제공할 수 있다. The present invention can provide a health functional food composition for preventing or improving arthritis, comprising a peony and licorice mixed extract.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염 예방 또는 치료용 수의학적 조성물을 제공할 수 있다. The present invention may provide a veterinary composition for preventing or treating arthritis comprising a peony and licorice mixed extract.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염 예방 또는 개선용 사료 첨가제를 제공할 수 있다. The present invention may provide a feed additive for preventing or improving arthritis comprising a peony and licorice mixed extract.
본 발명의 작약 및 감초 혼합 추출물은 동물실험에서 골관절염이 유발된 동물의 염증인자인 IL-1β, IL-6, TNF-α 및 MMP-9의 발현을 감소시키고, 연골손상을 억제하는 효과가 있다. 이에 본 발명의 작약 및 감초 혼합 추출물은 동물의 골관절염을 예방 또는 치료하는 효과가 있다. The mixed extract of peony and licorice of the present invention has the effect of reducing the expression of IL-1β, IL-6, TNF-α and MMP-9, which are inflammatory factors in animals induced by osteoarthritis in animal experiments, and inhibiting cartilage damage . Therefore, the peony and licorice mixed extract of the present invention is effective in preventing or treating osteoarthritis in animals.
도 1은 작약 및 감초 혼합 추출물의 관절조직내 염증인자인 IL-1β, IL-6, TNF-α 및 MMP-9의 발현 억제 효과를 확인한 결과이다.
도 2는 MIA(monosodium iodoacetate)로 유도하는 골관절염 동물모델에 작약 및 감초 혼합 추출물을 100 또는 250 mg/kg/day의 농도로 2주일간 경구 투여한 뒤, 연골조직의 변화를 분석한 조직병리학적 결과이다. 1 is a result confirming the effect of inhibiting the expression of IL-1β, IL-6, TNF-α and MMP-9, which are inflammatory factors in joint tissues, of a mixed extract of peony and licorice.
Figure 2 is a histopathological result of analyzing changes in cartilage tissue after oral administration of a mixed extract of peony and licorice at a concentration of 100 or 250 mg/kg/day for 2 weeks to an animal model of osteoarthritis induced by monosodium iodoacetate (MIA). to be.
이하에서 본 발명을 자세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명자들은 천연물에서 개 고양이 관절염 예방 및 치료용 수의학적 약학 조성물을 연구하던 중, 작약 및 감초 혼합추출물이 관절 조직내 염증인자인 IL-1β, IL-6, TNF-α 및 MMP-9의 발현을 억제하고 (도 1), MIA로 유도하는 골관절염 동물모델에서 연골조직의 손상을 억제할 수 있음(도 2)을 확인하여 본 발명을 완성하였다. While the present inventors were studying veterinary pharmaceutical compositions for preventing and treating arthritis in dogs and cats in natural products, the peony and licorice extracts expressed the inflammatory factors IL-1β, IL-6, TNF-α and MMP-9 in joint tissues. The present invention was completed by confirming that cartilage tissue damage can be suppressed (FIG. 1) and cartilage tissue damage in an animal model of MIA-induced osteoarthritis (FIG. 2).
본 발명은 작약 및 감초 혼합추출을 포함하는 관절염의 예방 또는 치료용 약학적 조성물을 제공할 수 있다. The present invention may provide a pharmaceutical composition for preventing or treating arthritis, comprising a mixed extract of peony and licorice.
본 발명은 monosodium iodoacetate (MIA, Sigma, USA)를 이용하여 골관절염을 유도한 동물모델에 작약 및 감초 혼합 추출물을 처리한 결과, 관절 조직내 염증인자인 IL-1β, IL-6, TNF-α 및 MMP-9의 발현을 억제하고 (도 1), 연골조직의 손상을 억제할 수 있음(도 2)을 확인하였다. 따라서 작약 및 감초 혼합 추출물이 개 고양이의 관절염에 효과적인 것을 확인하였다. In the present invention, as a result of treatment with a mixed extract of peony and licorice in an animal model inducing osteoarthritis using monosodium iodoacetate (MIA, Sigma, USA), the inflammatory factors IL-1β, IL-6, TNF-α and It was confirmed that the expression of MMP-9 was suppressed (FIG. 1) and that it was possible to inhibit damage to cartilage tissue (FIG. 2). Therefore, it was confirmed that the mixed extract of peony and licorice was effective for arthritis in dogs and cats.
작약은 예를 들면 학명 Paeonia lactiflora Pallas인 작약일 수 있고, 감초는 예를 들면 학명 Glychrrhiza uralensis Fischer인 감초일 수 있으나, 이에 제한되는 것은 아니다.The peony may be, for example, a peony with a scientific name of Paeonia lactiflora Pallas, and the licorice may be, for example, a licorice with a scientific name of Glychrrhiza uralensis Fischer, but is not limited thereto.
상기 각각 약재의 추출 부위는 특별히 한정되지 않으며 모든 부위의 사용이 가능하나, 바람직하게는 뿌리를 사용할 수 있다.The extraction site of each of the above medicines is not particularly limited and any site can be used, but preferably, the root can be used.
추출 용매는 특별히 한정되지 않으며, 예를 들면, 물 또는 유기용매를 사용할 수 있고, 유기용매로는 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산 (cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있으나, 이에 제한되지는 않는다. 바람직하게는 물을 사용할 수 있다.The extraction solvent is not particularly limited, and for example, water or an organic solvent may be used, and the organic solvent is methanol, ethanol, propanol, isopropanol, butanol, etc. containing 1 to 4 alcohols, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclo Various solvents, such as hexane (cyclohexane), may be used alone or in combination, but is not limited thereto. Preferably, water can be used.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있으며, 바람직하게는 열수추출법일 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 본 발명에 따른 추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다. 열수 추출의 경우의 구체적인 예를 들자면, 약재 중량의 3 내지 20배, 구체적으로 10배의 물을 가하여, 온도 80 내지 100℃, 구체적으로 90℃로 1시간 내지 24시간, 구체적으로 8시간 추출할 수 있으나, 이에 제한되는 것은 아니다.As the extraction method, any one of methods such as hot water extraction method, cold extraction method, reflux cooling extraction method, solvent extraction method, steam distillation method, ultrasonic extraction method, elution method, compression method, etc. can be selected and used, and it may be preferably a hot water extraction method. In addition, the desired extract may be further subjected to a conventional fractionation process, and may be purified using a conventional purification method. There is no limitation on the method for preparing the extract according to the present invention, and any known method may be used. As a specific example in the case of hot water extraction, 3 to 20 times, specifically, 10 times the weight of the drug is added, and the temperature is 80 to 100 ° C., specifically 90 ° C. for 1 hour to 24 hours, specifically for 8 hours. However, the present invention is not limited thereto.
발명에 따른 추출물은 상기 추출 이후에 필요에 따라 여과, 농축, 건조 등의 공정을 행한 것일 수 있다. 그러나 조건은 한정되지 않고 당 분야에 공지된 방법, 통상적으로 행해지는 조건으로 수행될 수 있다.The extract according to the present invention may be subjected to a process such as filtration, concentration, drying, etc. as needed after the extraction. However, the conditions are not limited and may be carried out by methods known in the art, and conditions commonly used.
상기 작약 및 감초의 함량비는 특별히 한정되지 않으나, 작약 및 감초는 10:1 내지 1:1의 중량비율로 혼합되는 것이 바람직하고, 2:1의 중량비율로 혼합하는 것이 가장 바람직하다.The content ratio of the peony and licorice is not particularly limited, but the peony and licorice are preferably mixed in a weight ratio of 10:1 to 1:1, and most preferably mixed in a weight ratio of 2:1.
상기 관절염은 노화, 외상, 자가면역, 대사질환으로 이루어진 군으로부터 선택되는 어느 하나 이상 것으로 인할 수 있고, 바람직하게는 노화일 수 있으나, 이에 제한되는 것은 아니다.The arthritis may be due to any one or more selected from the group consisting of aging, trauma, autoimmune, and metabolic diseases, and may preferably be aging, but is not limited thereto.
상기 작약 및 감초 혼합 추출물의 농도는 특별히 한정되지 않으며, 바람직하게는 1 내지 1000 mg/kg일 수 있고 더 바람직하게는 100 내지 250 mg/kg일 수 있다.The concentration of the peony and licorice mixed extract is not particularly limited, and may be preferably 1 to 1000 mg/kg, and more preferably 100 to 250 mg/kg.
상기 조성물은 그 용도에 따라 상기 추출물을 유효한 양, 또는 유효 성분으로서 포함할 수 있다. 상기 유효한 양은 개체에 따라 적절하게 선택할 수 있다. 질환 내지 상태의 중증도, 개체의 연령, 체중, 건강, 성별, 개체의 추출물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 투여 기간, 상기 조성물과 배합 또는 동시 사용되는 다른 조성물을 포함한 요소 및 기타 생리 내지 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The composition may include the extract in an effective amount or as an active ingredient depending on its use. The effective amount can be appropriately selected depending on the individual. the severity of the disease or condition, the subject's age, weight, health, sex, the subject's sensitivity to the extract, the time of administration, the route of administration and the rate of excretion, the duration of administration, factors including other compositions used in combination with or concurrently with the composition, and others It may be determined according to factors well known in the field of physiology or medicine.
본 발명에 따른 상기 추출물을 포함하는 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition comprising the extract according to the present invention is in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to a conventional method. It can be formulated and used.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염의 예방 또는 개선용 건강기능식품 조성물을 제공할 수 있다. 상기 작약 및 감초 혼합 추출물은 상기 약학적 조성물에서 사용된 것과 같으므로 상기 기재로 설명을 대신한다. The present invention can provide a health functional food composition for preventing or improving arthritis, comprising a peony and licorice mixed extract. Since the peony and licorice mixed extract is the same as used in the pharmaceutical composition, the description is replaced with the above description.
발명에 따른 식품 조성물은 당업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다. 일반 식품으로는 이에 한정되지 않지만 음료(알콜성 음료 포함), 과실 및 그의 가공식품(예: 과일통조림, 병조림, 잼, 마아말레이드 등), 어류, 육류 및 그 가공식품(예: 햄, 소시지 콘비이프 등), 빵류 및 면류(예: 우동, 메밀국수, 라면, 스파게이트, 마카로니 등), 과즙, 각종 드링크, 쿠키, 엿, 유제품(예: 버터, 치이즈 등), 식용 식물 유지, 마아가린, 식물성 단백질, 레토르트 식품, 냉동식품, 각종 조미료(예: 된장, 간장, 소스 등) 등에 본 발명의 작약 및 감초 혼합 추출물을 첨가하여 제조할 수 있다. 또한, 영양보조제로는 이에 한정되지 않지만 캡슐, 타블렛, 환 등에 본 발명의 작약 및 감초 혼합 추출물을 첨가하여 제조할 수 있다. 또한, 건강기능식품으로는 이에 한정되지 않지만 예를 들면, 본 발명의 작약 및 감초 혼합 추출물 자체를 차, 쥬스 및 드링크의 형태로 제조하여 음용(건강음료)할 수 있도록 액상화, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. 또한, 본 발명의 작약 및 감초 혼합 추출물을 식품 첨가제의 형태로 사용하기 위해서는 분말 또는 농축액 형태로 제조하여 사용할 수 있다. 또한, 본 발명의 작약 및 감초 혼합 추출물과 관절염 예방 또는 개선 효과가 있다고 알려진 공지의 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다. The food composition according to the invention can be prepared in various forms according to conventional methods known in the art. Common foods include, but are not limited to, beverages (including alcoholic beverages), fruits and their processed foods (eg, canned fruit, bottled, jam, marmalade, etc.), fish, meat and their processed foods (eg, ham, sausages) Corn beef, etc.), breads and noodles (eg udon noodles, soba noodles, ramen, spagate, macaroni, etc.), fruit juice, various drinks, cookies, syrup, dairy products (eg butter, cheese, etc.), edible vegetable oils and fats, margarine , vegetable protein, retort food, frozen food, various seasonings (eg, soybean paste, soy sauce, sauce, etc.) can be prepared by adding the peony and licorice mixed extract of the present invention. In addition, the nutritional supplement is not limited thereto, but may be prepared by adding the peony and licorice mixed extract of the present invention to capsules, tablets, pills, and the like. In addition, although not limited to this as a health functional food, for example, the peony and licorice mixed extract of the present invention can be prepared in the form of tea, juice, and drink, and liquefied, granulated, encapsulated, and It can be consumed in powder form. In addition, in order to use the peony and licorice mixed extract of the present invention in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate. In addition, it can be prepared in the form of a composition by mixing the peony and licorice extract of the present invention with a known active ingredient known to have an arthritis preventing or improving effect.
본 발명의 작약 및 감초 혼합 추출물을 건강음료로 이용하는 경우, 상기 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ～ 0.04 g, 바람직하게는 약 0.02 ～ 0.03g 이다.When the mixed extract of peony and licorice of the present invention is used as a health drink, the health drink composition may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional drink. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as taumatine, stevia extract; A synthetic sweetener such as saccharin or aspartame may be used. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
본 발명의 작약 및 감초 혼합 추출물은 관절염 예방 또는 개선용 식품 조성물의 유효성분으로 함유될 수 있는데, 그 양은 관절염 예방 및 개선 작용을 달성하기에 유효한 양으로 특별히 한정되는 것은 아니나, 전체 조성물 총 중량에 대하여 0.01 내지 100 중량%인 것이 바람직하다. 본 발명의 식품 조성물은 작약 및 감초 혼합 추출물과 함께 관절염 예방 및 개선용 조성물에 효과가 있는 것으로 알려진 다른 활성 성분과 함께 혼합하여 제조될 수 있다. The peony and licorice extract of the present invention may be contained as an active ingredient in a food composition for preventing or improving arthritis, and the amount is not particularly limited to an effective amount to achieve the prevention and improvement of arthritis, but is based on the total weight of the composition. It is preferable that it is 0.01 to 100% by weight with respect to it. The food composition of the present invention can be prepared by mixing the peony and licorice mixed extract with other active ingredients known to be effective in the composition for preventing and improving arthritis.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강식품은 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid, pectic acid salts, alginic acid, alginic acid salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, It may contain glycerin, alcohol or a carbonation agent and the like. In addition, the health food of the present invention may contain fruit for the production of natural fruit juice, fruit juice beverage, or vegetable beverage. These components may be used independently or in combination. The proportion of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 동물의 관절염의 예방 또는 치료용 수의학적 조성물을 제공할 수 있다. The present invention may provide a veterinary composition for preventing or treating arthritis in animals, comprising a peony and licorice mixed extract.
본 발명의 작약 및 감초 혼합 추출물을 포함하는 수의학적 조성물은 통상의 방법에 따른 적절한 부형제 및 희석제를 더 포함할 수 있다. 본 발명의 작약 및 감초 혼합 추출물을 포함하는 수의학적 조성물에 포함될 수 있는 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 세탄올, 스테아릴알콜, 유동파라핀, 솔비탄모노스테아레이트, 폴리소르베이트 60, 메칠파라벤, 프로필파라벤 및 광물유를 들 수 있다.The veterinary composition comprising the peony and licorice extract of the present invention may further include an appropriate excipient and diluent according to a conventional method. Excipients and diluents that may be included in the veterinary composition comprising the peony and licorice mixed extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, Gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, cetanol, stearyl alcohol, liquid paraffin, sorbitan monostearate, polysorbate 60, methylparaben, propylparaben, and mineral oil.
본 발명에 따른 작약 및 감초 혼합 추출물을 포함하는 수의학적 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향신료, 유화제, 방부제 등을 추가로 포함할 수 있는데, 본 발명에 의한 수의학적 조성물은 동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 잘 알려진 방법을 사용하여 제형화될 수 있고, 제형은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 용액, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 좌제, 멸균 주사용액, 멸균 외용제 등의 형태일 수 있다.The veterinary composition comprising the mixed extract of peony and licorice according to the present invention may further include a filler, an anti-aggregant, a lubricant, a wetting agent, a spice, an emulsifier, and a preservative, and the veterinary composition according to the present invention is administered to an animal It can be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after release, the formulations being powders, granules, tablets, capsules, suspensions, emulsions, solutions, syrups, It may be in the form of an aerosol, soft or hard gelatin capsule, suppository, sterile injection solution, sterile external preparation, and the like.
본 발명에 의한 수의학적 조성물은 그 용도에 따라 상기 추출물을 유효한 양, 또는 유효 성분으로서 포함할 수 있다. 상기 유효한 양은 동물의 개체에 따라 적절하게 선택할 수 있다. 질환 내지 상태의 중증도, 개체의 연령, 체중, 건강, 성별, 개체의 추출물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 투여 기간, 상기 조성물과 배합 또는 동시 사용되는 다른 조성물을 포함한 요소 및 기타 생리 내지 수의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The veterinary composition according to the present invention may contain the extract in an effective amount or as an active ingredient, depending on its use. The effective amount can be appropriately selected depending on the individual of the animal. the severity of the disease or condition, the subject's age, weight, health, sex, the subject's sensitivity to the extract, the time of administration, the route of administration and the rate of excretion, the duration of administration, factors including other compositions used in combination with or concurrently with the composition, and others It may be determined according to factors well known in the field of physiology or veterinary medicine.
상기 동물은 개 또는 고양이 일 수 있으나, 이에 제한되는 것은 아니다. The animal may be a dog or a cat, but is not limited thereto.
본 발명은 작약 및 감초 혼합 추출물을 포함하는 관절염 예방 또는 개선용 사료 첨가제를 제공할 수 있다. The present invention may provide a feed additive for preventing or improving arthritis comprising a peony and licorice mixed extract.
상기 사료 첨가제는 작약 및 감초 혼합 추출물을 포함하는 고 농축액, 분말 또는 과립형태일 수 있다. 본 발명의 사료 첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산 등의 유기산이나 인산나트륨, 인산칼륨, 산성피로인산염, 폴리인산염(중합인산염) 등의 인산염이나 폴리페놀, 카테킨(catechin), 알파-토코페롤, 로즈메리 추출물(rosemary extract), 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중에서 선택된 하나 이상을 추가로 포함할 수 있다.The feed additive may be in the form of a high concentrate, powder or granule containing a peony and licorice mixed extract. The feed additive of the present invention includes organic acids such as citric acid, humic acid, adipic acid, lactic acid, and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polyphosphate), polyphenol, catechin, alpha -Tocopherol, rosemary extract (rosemary extract), vitamin C, green tea extract, licorice extract, chitosan, tannic acid, may further include one or more selected from natural antioxidants such as phytic acid.
본 발명의 작약 및 감초 추출물을 포함하는 동물사료 첨가제 및 이를 포함하는 사료는 보조성분으로 아미노산, 무기염류, 비타민, 항생물질, 항균물질, 항산화, 항곰팡이 효소, 소화 및 흡수향상제, 성장촉진제, 질병예방제등과 같은 물질과 함께 사용될 수 있다. The animal feed additive comprising the peony and licorice extract of the present invention and the feed containing the same are amino acids, inorganic salts, vitamins, antibiotics, antibacterial substances, antioxidants, antifungal enzymes, digestion and absorption enhancers, growth promoters, diseases It can be used together with substances such as prophylactic agents.
상기 사료 첨가제는 동물에게 단독으로 식용 담체 중에서 다른 사료 첨가제와 조합되어 투여될 수 있다. 또한, 상기 사료첨가제는 탑 드레싱으로서 또는 이들을 동물 사료에 직접 혼합하거나 또는 사료와 별도로, 별도의 경구 제형으로, 주사 또는 경피로 또는 다른 성분과 조합하여 쉽게 투여할 수 있다. 통상적으로, 당 업계에 잘 알려진 바와 같이 단독 일일 투여량 또는 분할 일일 투여량을 사용할 수 있다. 상기 사료 첨가제를 동물 사료와 별도로 투여할 경우, 당 업계에 잘 알려진 바와 같이 추출물의 투여 형태는 이들을 비-독성 제약상 허용 가능한 식용 담체와 조합하여 즉석 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수 전분, 락토스, 수크로스, 콩 플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌 글리콜일 수 있다. 고체 담체가 사용될 경우, 추출물의 투여형은 정제, 캡슐제, 산제, 토로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 연 젤라틴 캡슐제, 또는 시럽제 또는 액체 현탁액제, 에멀젼제 또는 용액제의 투여 형태일 수 있다. 또한, 투여 형태는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액 촉진제 등을 함유할 수 있다. 또한, 작약 및 감초 추출물이 사료 첨가제로 포함되는 동물사료는 동물의 식이 요구를 충족시키는데 통상적으로 사용되는 임의의 단백질-함유 유기 곡분일 수 있다. 이러한 단백질-함유 곡분은 통상적으로 옥수수, 콩 곡분 또는 옥수수/콩 곡분 믹스로 주로 구성되어 있다. 상기의 사료 첨가제는 침지, 분무 또는 혼합하여 상기 동물사료에 첨가하여 이용될 수 있다. 본 발명의 수의학적 조성물 또는 사료첨가제는 반려동물의 식이에 적용할 수 있다.The feed additive may be administered alone to the animal in combination with other feed additives in an edible carrier. In addition, the feed additives can be easily administered as a top dressing or directly mixed with animal feed or separately from the feed, as a separate oral formulation, by injection or transdermal route, or in combination with other ingredients. Typically, a single daily dose or divided daily doses may be used as is well known in the art. When the feed additives are administered separately from the animal feed, the dosage forms of the extracts can be prepared into immediate release or sustained release formulations by combining them with a non-toxic pharmaceutically acceptable edible carrier, as is well known in the art. Such edible carriers may be solid or liquid, for example corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the dosage form of the extract may be a tablet, capsule, powder, tallow or sugar-containing tablet or top dressing in microdispersed form. When a liquid carrier is used, it may be in the form of soft gelatin capsules, or in the form of syrups or liquid suspensions, emulsions or solutions. The dosage form may also contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters, and the like. In addition, the animal feed in which the peony and licorice extracts are included as feed additives may be any protein-containing organic grain flour commonly used to meet the dietary needs of animals. Such protein-containing flours typically consist primarily of corn, soy flour or corn/soy flour mix. The feed additive may be used by adding to the animal feed by immersion, spraying, or mixing. The veterinary composition or feed additive of the present invention can be applied to the diet of companion animals.
본 발명은 또한 작약 및 감초 혼합 추출물을 포함하는 관절염 예방 또는 개선용 기능성 사료 조성물을 제공할 수 있다. The present invention may also provide a functional feed composition for preventing or improving arthritis comprising a peony and licorice mixed extract.
상기 조성물이 기능성 사료 조성물인 경우, 당해 기술분야에 공지되어 있는 통상적인 사료의 제형으로 제제화될 수 있다. 상기 사료용 조성물은 예를 들어 산제, 과립제, 정제, 환제, 캅셀제, 현탁액, 유제, 시럽제, 침제, 액제, 엑스제 등의 일반적인 제형으로 제조될 수도 있고, 임의의 사료 형태로 제조될 수도 있다. 상기 사료의 제제화를 위해 수의영양학적으로 허용 가능한 첨가제를 사용할 수 있으며, 제조하고자 하는 제형의 제조에 당해 기술분야에서 사용 가능한 것으로 공지되어 있는 임의의 첨가제가 이용될 수 있다. When the composition is a functional feed composition, it may be formulated in the formulation of a conventional feed known in the art. The composition for feed may be prepared in general formulations such as powders, granules, tablets, pills, capsules, suspensions, emulsions, syrups, needles, liquids, extracts, etc., or may be prepared in any form of feed. A veterinary and nutritionally acceptable additive may be used for formulating the feed, and any additive known to be usable in the art may be used for the preparation of the dosage form to be prepared.
상기 기능성사료 조성물 중의 상기 추출물의 함량은 사용 목적(예방 또는 개선)에 따라 적합하게 결정될 수 있다. 일반적으로, 전체 사료 중량의 0.01 내지 20 중량%로 포함할 수 있다. The content of the extract in the functional feed composition may be suitably determined according to the purpose of use (prevention or improvement). In general, it may be included in an amount of 0.01 to 20% by weight of the total feed weight.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
실시예 1. 작약 및 감초 혼합 추출물의 제조Example 1. Preparation of peony and licorice mixed extract
작약(Peony Root) 및 감초(Licorice) 혼합 추출물들을 제조하기 위하여, 작약은 CK허브 (보은, 충청북도, 한국), 감초는 감초영농조합 (제천, 충청북도, 한국)에서 구입하여 사용하였다. 용기에 작약(Paeonia lactiflora Pallas) 100중량부, 감초(Glychrrhiza uralensis Fischer) 50 중량부를 넣고, 물 1500 중량부를 넣었다. 이후 90℃±5℃로 8시간 동안 열수 추출하여 추출물을 얻고, 이를 50㎛ 필터로 여과하여 여과물을 얻었다. 상기 여과물을 말토덱스트린과 고형분 중량 기준 3:7로 혼합하고, 50℃±5℃로 고형분 함량이 35%±5%가 되도록 농축하였다. 농축물을 170℃±30℃에서 분무 건조하여 수분 함량 5% 이하의 추출물을 얻었다(수율 40±5%부형제 포함)To prepare Peony Root and Licorice mixed extracts, Peony was purchased from CK Herb (Boeun, Chungcheongbuk-do, Korea), and Licorice was purchased from Licorice Farming Association (Jecheon, Chungcheongbuk-do, Korea) and used. 100 parts by weight of peony (Paeonia lactiflora Pallas) and 50 parts by weight of licorice (Glychrrhiza uralensis Fischer) were put in a container, and 1500 parts by weight of water was added. Thereafter, hot water extraction was performed at 90° C.±5° C. for 8 hours to obtain an extract, which was filtered through a 50 μm filter to obtain a filtrate. The filtrate was mixed with maltodextrin in a ratio of 3:7 by solids weight, and concentrated to a solid content of 35%±5% at 50°C±5°C. The concentrate was spray dried at 170°C±30°C to obtain an extract with a water content of 5% or less (yield 40±5% including excipients)
실시예 2. MIA(monosodium iodoacetate)에 의해 유도된 골관절염 동물모델에서 작약 및 감초 혼합 추출물이 염증인자 발현에 미치는 효과 확인Example 2. Confirmation of effects of mixed extracts of peony and licorice on the expression of inflammatory factors in an animal model of osteoarthritis induced by MIA (monosodium iodoacetate)
상기 실시예 1에서 제조한 작약 및 감초 혼합 추출물이 MIA로 유도한 골관절염 동물모델에서의 염증인자 발현에 미치는 영향을 확인하기 위하여, 골관절염 유발물질인 MIA(0.9% saline으로 60㎎/㎖의 농도로 희석)를 7주령 SD 랫트의 오른쪽 뒷다리 관절강 내에 50㎕씩 투여하여 골관절염을 유도한 후, 작약 및 감초 혼합 추출물(100 및 250㎎/㎏)을 1일 1회 총 14일 동안 경구 투여하였으며, 골관절염이 유발된 관절에서 mRNA를 추출하여 염증유발인자 IL-1β, IL-6, TNF-α, MMP-9의 발현을 PCR을 통해 확인하였다. In order to confirm the effect of the peony and licorice mixed extract prepared in Example 1 on the expression of inflammatory factors in an animal model of MIA-induced osteoarthritis, the osteoarthritis-inducing substance MIA (0.9% saline at a concentration of 60 mg/ml) After induced osteoarthritis by administering 50 μl each into the joint cavity of the right hind leg of a 7-week-old SD rat, peony and licorice mixed extract (100 and 250 mg/kg) were orally administered once a day for a total of 14 days, osteoarthritis By extracting mRNA from the induced joint, the expression of the proinflammatory factors IL-1β, IL-6, TNF-α, and MMP-9 was confirmed through PCR.
그 결과, 도 1에 나타난 바와 같이 MIA에 의해 골관절염이 유발된 샘플에서는 염증유발인자의 발현이 증가하는 것을 확인한 반면, 작약 및 감초 혼합 추출물 처리시 증가한 인자들의 발현이 감소하였다. 이를 통해 본 추출물이 골관절염에 의해 유발된 염증을 억제한다는 것을 알 수 있었다.As a result, as shown in FIG. 1 , it was confirmed that the expression of inflammation-inducing factors was increased in the sample induced by MIA with osteoarthritis, whereas the expression of the factors increased when the peony and licorice mixed extract was treated was decreased. Through this, it was found that this extract suppressed inflammation induced by osteoarthritis.
실시예 3. MIA(monosodium iodoacetate)에 의해 유도된 골관절염 동물모델에서 작약 및 감초 혼합 추출물에 의한 연골조직의 조직병리학적 변화 확인Example 3. Confirmation of histopathological changes in cartilage tissue by the mixed extract of peony and licorice in an animal model of osteoarthritis induced by MIA (monosodium iodoacetate)
골관절염이 유발된 랫트의 무릎 부위를 절단하여, 10% EDTA가 포함된 10% 포르말린 용액에 넣어 관절 조직을 탈회 시켰다. 그 후 파라핀 왁스에 관절 조직을 넣고 고정한 다음 관상면 절단(coronal section)을 실시하여 파라핀으로 고정한 조직을 7㎛의 크기로 자른 뒤, 사프라닌 O(Safranin-O) 염색을 실시하여 조직 상태를 확인하였다. 연골의 주요 성분인 프로테오글리칸(proteoglycan) 층을 염색하는 사프라닌 O 염색을 통해 연골 조직의 손상 여부를 확인하였다. 연골조직의 손상정도는 국제골관절염 연구회 (Osteoarthritis Research Society International, OARSI) 평가 척도 (scoring system)을 이용하여 연골 손상 정도를 다음과 같이 점수화 하여 평가하였다. (0 = 변성 없음, 1 = 연골 표면에 경미한 변성, 2 = 위쪽 중앙부위로 조금 확대된 변성, 3 = 중앙 부위까지 침범한 중등도 변성, 4 = 깊은 심부까지 침범한 변성, 5 = 전체적인 심한 변성). 그 결과, 도 2에 나타난 바와 같이 사프라닌 O 염색 결과, 골관절염 유발군(MIA)은 붉게 염색된 정상 연골 조직이 골관절염으로 인해 파괴되어 프로테오글리칸 조직이 사라진 반면, 작약 및 감초 혼합 추출물을 처치한 경우 붉게 염색된 프로테오글리칸 조직이 활막 주변에 많이 분포하였으며, OARSI 평가 척도에서도 연골의 손상이 작약 및 감초 혼합 추출물을 처치로 인하여 억제되었다. 이를 통해 작약 및 감초 혼합 추출물이 MIA에 의해 유도되는 골관절염을 억제하는 것을 확인하였다. The osteoarthritis-induced rat knee was cut, and the joint tissue was demineralized by putting it in a 10% formalin solution containing 10% EDTA. After that, joint tissue was put in paraffin wax and fixed, and then coronal section was performed to cut the paraffin-fixed tissue to a size of 7 μm, and then stained with Safranin-O to determine the tissue state. Confirmed. It was confirmed whether the cartilage tissue was damaged through safranin O staining, which stains the proteoglycan layer, which is a major component of cartilage. The degree of cartilage damage was evaluated by scoring the degree of cartilage damage as follows using the Osteoarthritis Research Society International (OARSI) scoring system. (0 = no degeneration, 1 = mild degeneration of the cartilage surface, 2 = slightly enlarged degeneration to the upper central region, 3 = moderate degeneration extending to the central region, 4 = degeneration affecting the deep depths, 5 = severe overall degeneration). As a result, as shown in FIG. 2 , in the case of safranin O staining, in the osteoarthritis-inducing group (MIA), the red-stained normal cartilage tissue was destroyed due to osteoarthritis and the proteoglycan tissue disappeared, whereas peony and licorice mixed extract were treated. A lot of red-stained proteoglycan tissue was distributed around the synovial membrane, and even in the OARSI evaluation scale, cartilage damage was inhibited by the treatment with the peony and licorice mixed extract. Through this, it was confirmed that the mixed extract of peony and licorice inhibited osteoarthritis induced by MIA.
Claims (8)
A feed additive for preventing or improving arthritis, comprising a peony and licorice mixed extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200077835A KR20220000185A (en) | 2020-06-25 | 2020-06-25 | A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200077835A KR20220000185A (en) | 2020-06-25 | 2020-06-25 | A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220000185A true KR20220000185A (en) | 2022-01-03 |
Family
ID=79348441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200077835A KR20220000185A (en) | 2020-06-25 | 2020-06-25 | A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220000185A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102632034B1 (en) * | 2022-12-09 | 2024-02-02 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating arthritis and joint pain comprising mixed extract of Alpiniae Oxyphyllae, Paeonia lactiflora and Glycyrrhiza uralensis as effective component |
-
2020
- 2020-06-25 KR KR1020200077835A patent/KR20220000185A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102632034B1 (en) * | 2022-12-09 | 2024-02-02 | 한국 한의학 연구원 | Composition for preventing, ameliorating or treating arthritis and joint pain comprising mixed extract of Alpiniae Oxyphyllae, Paeonia lactiflora and Glycyrrhiza uralensis as effective component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101982326B1 (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| KR102448542B1 (en) | Composition for relieving menopausal symptom | |
| KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
| KR20130065618A (en) | Composition comprising water extracts from fomitella fraxinea (fr.) imaz. for treating or preventing obesity | |
| KR20220000185A (en) | A pharmaceutical composition for the prevention or treatment of arthritis comprising peony and licorice mixed extract | |
| KR20140129492A (en) | Compositions Comprising a Leaf Extract of Cudrania tricuspidata for the Prevention and Treatment of Arthritis disease | |
| KR100555904B1 (en) | A herbal mixture extract of Pleurotus eryngii and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR20170014329A (en) | A food composition comprising extract of donkey | |
| KR101896815B1 (en) | Health functional food composition for anorexia improvement and pharmaceutical composition for preventing or treating anorexia improvement | |
| KR102632034B1 (en) | Composition for preventing, ameliorating or treating arthritis and joint pain comprising mixed extract of Alpiniae Oxyphyllae, Paeonia lactiflora and Glycyrrhiza uralensis as effective component | |
| KR102612089B1 (en) | Composition for preventing and treating osteoporosis containing extract of Lindera obtusiloba leaf as an active ingredient | |
| KR102561733B1 (en) | Composition for ameliorating blood circulation comprising extract of Capsicum annuum by-product as effective component | |
| KR102025572B1 (en) | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component | |
| KR20220000186A (en) | A pharmaceutical composition for the prevention or treatment of keratoconjunctivitis sicca comprising a mixture of quercetin and Polygonum cuspidatum stem extract | |
| KR102092961B1 (en) | Pharmaceutical composition comprising the ethanol extract of abeliophyllum distichum as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR20230161340A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Staphylea bumalda extract as effective component | |
| KR20230161339A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component | |
| KR20230105651A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Hieracium umbellatum extract as effective component | |
| KR20230105650A (en) | Composition for preventing, ameliorating or treating arthritis and joint pain comprising Carpesium sp. plant extract as effective component | |
| KR20230161341A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Lysimachia mauritiana extract as effective component | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR20230044120A (en) | Composition for prevention, amelioration or treatment of arthritis comprising Glycine soja extract as effective component | |
| KR20230110176A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Tilia insularis extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |